Category: pharma & healthcare

As the first and only FDA approved antiviral treatment for COVID-19, Gilead’s remdesivir has been shown to prevent individuals at high risk of severe disease from being hospitalized. However, inherent eligibility and accessibility restrictions reduce i…

By coding for viral proteins that block immune detection of microbial threats, SARS-CoV-2 is able to establish infection and proliferate to high titers before the immune system can react. One of these proteins is open reading frame 6, or Orf6.

Scientists and epidemiologists around the world are alert to the possibility that yet another dangerous variant may arise. This is the context to understand the interest in a recent report of a new variant, B.1.640.2, in France.

A new study shines light onto the intricate and aberrant process by which hAEC2 cells turn into basal cells in response to severe alveolar injuries, a transformation that changes the architecture of the lungs and can lead to further damage as well as i…

The NYTimes published an article and a podcast on prenatal screening. Unfortunately, they botched many of the facts about NIPS and how it should be used.

With data suggesting children may be less protected against Omicron than previous SARS-CoV-2 variants, we need clarity on what drives risk and protection in younger populations. Why the virus largely spares children was anyone’s guess, until now.

Rockett et al. demonstrate that resistance to sotrovimab as a monotherapy rises rapidly in treated patients.

Vaccines have saved lives and prevented severe disease, with comparatively few adverse events. But, anti-vaccine groups persistently refer to mRNA vaccines as “experimental gene therapies.” Vaccines that use mRNA technology, however, aren’t gene therap…